Arginase I and the very low-density lipoprotein receptor are associated with phenotypic biomarkers for obesity

Nutrition

Volumn 28, Issue 6, 2012, Pages 635-639

  Kim, Oh Yoen ^a   Lee, Seung Min ^b   Chung, Ji Hyung ^a,c   Do, Hyun Joo ^b   Moon, Jiyoung ^b   Shin, Min Jeong ^b  

^a Yonsei University   (South Korea)

^b Korea University   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

Arginase I; Cardiovascular risk; Obesity; Soluble intercellular adhesion molecule 1; Very low density lipoprotein receptor

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADIPONECTIN RECEPTOR 1 GENE; ADIPONECTIN RECEPTOR 2 GENE; ADULT; AGED; ARGINASE I GENE; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; MALE; NITRIC OXIDE SYNTHASE 3 GENE; NORMAL HUMAN; OBESITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; UPREGULATION; VERY LOW DENSITY LIPOPROTEIN RECEPTOR GENE;

ADIPONECTIN; ADULT; AGED; APOLIPOPROTEINS B; ARGINASE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL; ENDOTHELIUM, VASCULAR; FEMALE; GENE EXPRESSION; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; OBESITY; PHENOTYPE; RECEPTORS, LDL; RNA, MESSENGER; TRIGLYCERIDES; UP-REGULATION;

EID: 84860646985     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2011.09.012     Document Type: Article

References (32)

1. The fourth Korea National Health & Nutrition Examination Survey (KNHANES III) 2008, South Korea Ministry of Health and Social Affairs, Ministry of Health and Welfare, Seoul.
2. Mello M.M., Studdert D.M., Brennan T.A. Obesity-the new frontier of public health law. N Engl J Med 2006, 354:2601-2610.
3. Hossain P., Kawar B.E., Nahas M. Obesity and diabetes in the developing world-a growing challenge. N Engl J Med 2007, 356:213-215.
4. Bolduc C., Yoshioka M., St-Amand J. Transcriptomic characterization of the long-term dihydrotestosterone effects in adipose tissue. Obesity (Silver Spring) 2007, 15:1107-1132.
5. Bouchard L., Rabasa-Lhoret R., Faraj M., Lavoie M.E., Mill J., Perusse L., Vohl M.C. Differential epigenomic and transcriptomic responses in subcutaneous adipose tissue between low and high responders to caloric restriction. Am J Clin Nutr 2010, 91:309-320.
6. Li H., Xie Z., Lin J., Song H., Wang Q., Wang K., et al. Transcriptomic and metabonomic profiling of obesity-prone and obesity-resistant rats under high fat diet. J Proteome Res 2008, 7:4775-4783.
7. Gobert A.P., Cheng Y., Akhtar M., Mersey B.D., Blumberg D.R., Cross R.K., et al. Protective role of arginase in a mouse model of colitis. J Immunol 2004, 173:2109-2117.
8. Durante W., Johnson F.K., Johnson R.A. Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol 2007, 34:906-911.
9. Tarry W.C., Markhoul R.G. l-Arginine improves endothelial-dependent vasorelaxation and reduces intimal hyperplasia after balloon injury. Arterioscler Thromb 1994, 14:938-943.
10. Tousoulis D., Antoniades C., Tentolouris C., Goumas G., Stefanadis C., Toutouzas P. l-Arginine in cardiovascular disease: dream or reality?. Vasc Med 2002, 7:203-211.
11. Hein T.W., Zhang C., Wang W., Chang C.I., Thengchaisri N., Kuo L. Ischemia-reperfusion selectively impairs nitric oxide-mediated dilation in coronary arterioles: counteracting role of arginase. FASEB J 2003, 17:2328-2330.
12. White A.R., Ryoo S., Li D., Champion H.C., Steppan J., Wang D., et al. Knockdown of arginase I restores NO signaling in the vasculature of old rats. Hypertension 2006, 47:245-251.
13. Zhang C., Hein T.W., Wang W., Miller M.W., Fossum T.W., McDonald M.M., et al. Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension 2004, 44:935-943.
14. Takahashi S., Sakai J., Fujino T., Miyamori I., Yamamoto T.T. The very low density lipoprotein (VLDL) receptor-a peripheral lipoprotein receptor for remnant lipoproteins into fatty acid active tissues. Mol Cell Biochem 2003, 248:121-127.
15. Oka K., Pastore L., Kim I.H., Merched A., Nomura S., Lee H.J., et al. Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor. Circulation 2001, 103:1274-1281.
16. Goudriaan J.R., Tacken P.J., Dahlmans V.E., Gijbels M.J., van Dijk K.W., Havekes L.M., Jong M.C. Protection from obesity in mice lacking the VLDL receptor. Arterioscler Thromb Vasc Biol 2001, 21:1488-1493.
17. Wu G., Bazer F.W., Davis T.A., Kim S.W., Li P., Marc Rhoads J., et al. Arginine metabolism and nutrition in growth, health and disease. Amino Acids 2009, 37:153-168.
18. Kashyap S.R., Lara A., Zhang R., Park Y.M., DeFronzo R.A. Insulin reduces plasma arginase activity in type 2 diabetic patients. Diabetes Care 2008, 31:134-139.
19. Zhang C., Hein T.W., Wang W., Chang C.I., Kuo L. Constitutive expression of arginase in microvascular endothelial cells counteracts nitric oxide-mediated vasodilatory function. FASEB J 2001, 15:1264-1266.
20. Ochoa J.B., Bernard A.C., O'Brien W.E., Griffen M.M., Maley M.E., Rockich A.K., et al. Arginase I expression and activity in human mononuclear cells after injury. Ann Surg 2001, 233:393-399.
21. Sonoki T., Nagasaki A., Gotoh T., Takiguchi M., Takeya M., Matsuzaki H., Mori M. Coinduction of nitric-oxide synthase and arginase I in cultured rat peritoneal macrophages and rat tissues in vivo by lipopolysaccharide. J Biol Chem 1997, 272:3689-3693.
22. Alderton W.K., Cooper C.E., Knowles R.G. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001, 357:593-615.
23. Dudzinski D.M., Igarashi J., Greif D., Michel T. The regulation and pharmacology of endothelial nitric oxide synthase. Annu Rev Pharmacol Toxicol 2006, 46:235-276.
24. Weigert J., Neumeier M., Wanninger J., Wurm S., Kopp A., Schober F., et al. Reduced response to adiponectin and lower abundance of adiponectin receptor proteins in type 2 diabetic monocytes. FEBS Lett 2008, 582:1777-1782.
25. Felder T.K., Hahne P., Soyal S.M., Miller K., Hoffinger H., Oberkofler H., et al. Hepatic adiponectin receptors (ADIPOR) 1 and 2 mRNA and their relation to insulin resistance in obese humans. Int J Obes (Lond) 2010, 34:846-851.
26. Heiker J.T., Kosel D., Beck-Sickinger A.G. Molecular mechanisms of signal transduction via adiponectin and adiponectin receptors. Biol Chem 2010, 391:1005-1018.
27. Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423:762-769.
28. Yamauchi T., Nio Y., Maki T., Kobayashi M., Takazawa T., Iwabu M., et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007, 13:332-339.
29. Waki H., Yamauchi T., Kamon J., Ito Y., Uchida S., Kita S., et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 2003, 278:40352-40363.
30. Kadowaki T., Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005, 26:439-451.
31. Hamada T., Kotani K., Nagai N., Tsuzaki K., Sano Y., Matsuoka Y., et al. Genetic polymorphisms of the renin-angiotensin system and obesity-related metabolic changes in response to low-energy diets in obese women. Nutrition 2011, 27:34-39.
32. Barnard N.D., Noble E.P., Ritchie T., Cohen J., Jenkins D.J., Turner-McGrievy G., et al. D2 dopamine receptor Taq1A polymorphism, body weight, and dietary intake in type 2 diabetes. Nutrition 2009, 25:58-65.